The financing comes on top of the company's $900 million annual research and development investment in the U.S.

ArteraAI Prostate forecasts potential long-term outcomes of a patient's prostate cancer biopsy slide based on digital pathology images.

The company's CEO defended its feature as a wellness tool under the 21st Century Cures Act, combatting the FDA’s claim that it qualifies as a regulated medical device.